Trans & Non-binary Reference Intervals While on Hormone Therapy Study

Launched by KING'S COLLEGE HOSPITAL NHS TRUST · Jul 15, 2020

Keywords

ClinConnect Summary

This clinical trial, called the Trans & Non-binary Reference Intervals While on Hormone Therapy Study, is focused on understanding the normal ranges for common blood tests in transgender and non-binary individuals who are undergoing hormone therapy. These reference intervals help doctors determine whether blood test results are normal or may indicate a health issue. Because transgender individuals on hormone therapy may have a mix of male and female characteristics, it’s important to establish accurate reference ranges specifically for them. This research aims to make it easier for doctors to identify any health problems in these patients more quickly.

To participate in this study, individuals must be 18 years or older, identify as transgender or non-binary, and have been taking hormone therapy (either testosterone or estrogen) for at least 12 months. Participants will visit cliniQ at King's College Hospital, complete a questionnaire, provide a urine sample, and have their blood tested as part of their regular monitoring. This study is looking to recruit 240 healthy participants. It's important to note that people with certain health conditions, such as severe diseases or those who are pregnant, will not be eligible to join. This research is supported by Viapath Group LLP and aims to improve health care for the transgender community.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Transgender or nonbinary people.
• • Aged 18 or older.
• • Taking testosterone or oestrogen therapy.
• • For 12 months or more.
• • Having routine hormone therapy monitoring at the clinic.
• Exclusion Criteria:
• • Unable to give informed consent (including participants who cannot communicate in English).
• • History of chronic liver disease, chronic kidney disease, diabetes, or severe cardiovascular disease (including myocardial infection, deep vein thrombosis, stroke and pulmonary embolism).
• • Blood test results that indicate severe disease.
• • Pregnant or within one year after childbirth.
• • Other conditions which could put participants at risk by participating, or which could influence the results of the study.